- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Anti-diabetic drugs.
Displaying page 1 of 3.
EudraCT Number: 2020-000472-37 | Sponsor Protocol Number: NN1436-4479 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week double blinded, multiregional, trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000442-34 | Sponsor Protocol Number: NN1436-4477 | Start Date*: 2020-09-09 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin ... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) PL (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000474-16 | Sponsor Protocol Number: NN1436-4480 | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-d... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000454-10 | Sponsor Protocol Number: NN1436-4478 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004047-20 | Sponsor Protocol Number: NN1250-4419 | Start Date*: 2018-08-28 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, cross-over, open-label, multi-centre trial comparing the effect of insulin degludec and insulin glargine 100U/mL, with or without OADs in subjects with type 2 diabetes using flash glu... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000225-30 | Sponsor Protocol Number: DMA-Clin-199-2013-001 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:DiaMedica USA Inc. | |||||||||||||
Full Title: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS... | |||||||||||||
Medical condition: Diabetes Mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003843-12 | Sponsor Protocol Number: PP-CT01 | Start Date*: 2017-01-16 |
Sponsor Name:PILA PHARMA | ||
Full Title: A Single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in 24 patients with diabetes me... | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004891-38 | Sponsor Protocol Number: A7211005 | Start Date*: 2008-02-11 | |||||||||||
Sponsor Name:Pfizer S.A | |||||||||||||
Full Title: Ensayo de 12 semanas, en fase 2A, aleatorizado, controlado con placebo y con enmascaramiento para el sujeto y el investigador, para evaluar la seguridad, la tolerabilidad y la eficacia de CE-326,59... | |||||||||||||
Medical condition: Control o tratamiento de la obesidad | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005385-38 | Sponsor Protocol Number: GFT505-315-1 | Start Date*: 2016-03-04 | ||||||||||||||||
Sponsor Name:Genfit SA | ||||||||||||||||||
Full Title: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis. | ||||||||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) and fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Completed) DE (Completed) CZ (Prematurely Ended) SE (Completed) IT (Prematurely Ended) PT (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002468-26 | Sponsor Protocol Number: DKprotokol(LIVE)v5 | Start Date*: 2011-08-12 | |||||||||||
Sponsor Name:Allan Flyvbjerg | |||||||||||||
Full Title: Liraglutide in chronic heart failure. A randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and witho... | |||||||||||||
Medical condition: Primary objective: To investigate the effect of Liraglutide 1.8 mg once daily compared to placebo on left ventricular eject fraction in Chromic heart failure patients with and without Type 2 diabe... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004965-22 | Sponsor Protocol Number: NN9535-4339 | Start Date*: 2017-06-08 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) HU (Completed) FR (Completed) FI (Completed) ES (Completed) SE (Completed) BG (Completed) GB (Completed) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001027-11 | Sponsor Protocol Number: AS07/1104-001 | Start Date*: 2005-06-03 |
Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust | ||
Full Title: Diabetes in the Very Elderly Trial | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004944-39 | Sponsor Protocol Number: NPJ005-DM2-0522 | Start Date*: 2018-04-27 | |||||||||||
Sponsor Name:neopharma Japan Co., Ltd | |||||||||||||
Full Title: A 24 Week, Phase IIa, Double blind, Randomized, Parallel Group, Placebo-controlled, Proof of Concept Study to Assess the Efficacy and Safety of Two Doses of 5 Aminolevulinic Acid Co-administered wi... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002801-20 | Sponsor Protocol Number: NN1250-4252 | Start Date*: 2017-02-10 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without ora... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) DK (Completed) EE (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000299-39 | Sponsor Protocol Number: NN9924-4635 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) SK (Completed) HU (Completed) BG (Completed) SI (Completed) PL (Completed) HR (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005967-25 | Sponsor Protocol Number: BVT.115959-005 | Start Date*: 2007-03-06 |
Sponsor Name:Biovitrum AB | ||
Full Title: A double-blind, placebo-controlled, randomized, parallel-group study evaluating the efficacy and tolerability of oral BVT.115959, a novel A2A agonist, versus placebo in the treatment of diabetic ne... | ||
Medical condition: Diabetic Neuropathic Pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) GB (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000881-23 | Sponsor Protocol Number: MYL-GAI-3002 | Start Date*: 2014-10-28 | |||||||||||
Sponsor Name:MYLAN GmbH | |||||||||||||
Full Title: AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS | |||||||||||||
Medical condition: Type 2 Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003219-20 | Sponsor Protocol Number: NN9535-4386 | Start Date*: 2018-09-13 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-ce... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) SI (Completed) EE (Completed) BG (Completed) LV (Completed) PL (Completed) GR (Completed) DE (Completed) CZ (Completed) LT (Completed) PT (Completed) ES (Completed) HR (Completed) HU (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016382-29 | Sponsor Protocol Number: P1736-05/34/09 | Start Date*: 2009-11-06 |
Sponsor Name:Piramal Life Sciences Limited | ||
Full Title: A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects wi... | ||
Medical condition: Diabetes mellitus, type 2 (Blood Glucose Lowering Effect)/ | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) HU (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019956-32 | Sponsor Protocol Number: - | Start Date*: 2010-09-09 | |||||||||||
Sponsor Name:Allan Vaag, Steno Diabetes Center | |||||||||||||
Full Title: Safety and efficacy of liraglutide as add-on to insulin and metformin therapy in type 2 diabetes patients | |||||||||||||
Medical condition: type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
